Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Travere Therapeutics will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.70
-1.42 (-0.54%)
AAPL  270.71
+3.10 (1.16%)
AMD  323.21
-11.42 (-3.41%)
BAC  52.66
+0.03 (0.06%)
GOOG  347.50
-1.02 (-0.29%)
META  671.34
-7.28 (-1.07%)
MSFT  429.25
+4.43 (1.04%)
NVDA  213.17
-3.44 (-1.59%)
ORCL  165.96
-7.00 (-4.05%)
TSLA  376.02
-2.65 (-0.70%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.